Massachusetts Department of Developmental Services Medication Review
|
|
|
- Belinda Reeves
- 5 years ago
- Views:
Transcription
1 University of Massachusetts Medical School Commonwealth Medicine Publications Commonwealth Medicine Massachusetts Department of Developmental Services Medication Review Alexandra Bonardi University of Massachusetts Medical School Gail Grossman Massachusetts Department of Developmental Services Emily Lauer University of Massachusetts Medical School Follow this and additional works at: Part of the Health Policy Commons, Health Services Administration Commons, Health Services Research Commons, Mental Disorders Commons, and the Pharmacy and Pharmaceutical Sciences Commons Repository Citation Bonardi, Alexandra; Grossman, Gail; and Lauer, Emily, "Massachusetts Department of Developmental Services Medication Review" (2012). Commonwealth Medicine Publications This material is brought to you by It has been accepted for inclusion in Commonwealth Medicine Publications by an authorized administrator of For more information, please contact
2 Massachusetts Department of Developmental Services Medication Review NASDDDS Reinventing Quality August 7, 2012 Alixe Bonardi 1, Gail Grossman 2 Emily Lauer 1 1 University of Massachusetts Medical School 2 Massachusetts Department of Developmental Services
3 Pharmacy (medication) use among adults in the MA DDS population DDS Medication Review Committee Clinical Reviews Population analyses Training Medicaid pharmacy claims analyses (2012) Study design and validation. Initial results from analysis of data match.
4 Pharmacotherapy is a common intervention in people with IDD In MA DDS population analysis, 62% were receiving one or more psychotropic medication (Rate was 47% when anticonvulsants removed) MA DDS (January 2003 Snapshot ; n=16,212 adults)
5 Top 10 Rx s to DMR Population over 7 months ( ) Rank Brand Name Class # of Prescriptions 1 Depakote Anticonvulsant Risperdal Atypical Antipsychotic Levoxyl Thyroid hormone Zyprexa Atypical Antipsychotic Carbamazepine Anticonvulsant Zoloft Antidepressant Neurontin Anticonvulsant Clonazepam Anticonvulsant Celexa Antidepressant Lorazepam Anxiolytic
6 Top Rx s to DMR Population over 7 mo. Rank Brand Name Class # of Prescriptions 11 Lipitor Cholesterol Phenobarbital Anticonvulsant Fluoxetine HCl Antidepressant Trazodone HCl Antidepressant Phenytoin Na Ext Anticonvulsant Buspirone HCl Anxiolytic Paxil Antidepressant Dilantin Anticonvulsant Seroquel Atypical Antipsychotic Protonix Ulcer/Reflux Disease
7 NCI: Takes medication for behavior problems ( ) Massachusetts All 20 Participating States 21% 24%
8 NCI: Takes medication for anxiety ( ) Massachusetts All 20 Participating States 35% 25%
9 Polypharmacy is also common MA DDS analysis (2005): Avg psychotropic medications (including anticonvulsants) 61% receiving anticonvulsants also received 1 or more other psychotropic medication 40% of those on anticonvulsants receive 2 or more types of anticonvulsants concurrently
10 Psychotropic Medications per Person over 1 month # of Psychotropics # of people % of population % % % % % % % % 8 72 <1% 9 26 <1% <1% >10 13 <1% Range: 0-11 psychotropic medications 9
11 Psychotropic medication use increases risk of health complications Weight gain Abnormal glucose metabolism (diabetes) Cardiovascular disturbances Oral health issues Extra pyramidal symptoms, TD. Lunsky & Elserafi (2011) Research in Developmental Disabilities
12 Prescribers are not always well prepared to treat the IDD population Majority of medical care from community health care providers. Communication difficulties may challenge ability to monitor response to medication. Complex medical picture can result in multiple prescribers CAN survey: 53% of medical school deans did not feel their graduates were competent to treat people with N/ID.
13 Ave No. Prescribers MA analysis of prescribers (2005) 50% of prescribers of psychotropics were generalists 2,637 practitioners prescribed non-anticonvulsant psychotropics More prescribers = More meds! The more practitioners prescribing, the more psychotropic medication received! No Psychtropics per Person 2.8
14 MA DDS Behavioral Supports Current initiatives include: Positive Behavioral Supports (PBS) training and interventions Updated curriculum re. restraints Medication Review Committee Clinical Review Provider Outreach Training and Continuing Education Analysis of Health Care and Claims Records
15 Membership: PhD psychologists (behaviorists) Psych. clinical nurse specialist (CNS) Clinical Pharmacist Internist (MD) Gerontologist (MD) Neurologist (MD) Psychiatrist (MD) RNs and NP Hospitalist (MD) * All with significant experience treating adults with IDD
16 Complex Case Consultation available through referral to the Med. Review Committee Referral through regional offices Treatment team invited to participate Average 2 reviews per meeting Results sent to regional/area office with request to forward to provider Direct consult with health care provider when requested.
17 Clinical Reviews impressions: Complicated intersection of behavioral and physical issues (e.g. pain) Earlier signs of age-related issues (dementia, changes in drug metabolism) Practitioners struggling with prescribing in a community setting (caregiver issues, hesitancy to titrate) Professional-to-professional outreach from team has included direct consultation, phone consultation.
18 Clinical Reviews: One year follow up Of those who were reviewed with recommendation to remove medications general improvement in function and impression of avoided psychiatric events. Where recommendations were not followed, individual continued to do poorly. As a group, those who were identified with emerging dementia showed continued decline in function.
19 Medication Review Committee guides DDS outreach to prescribers Analyses of DDS Health Care Records to identify top prescribers (regionally, by medication, specialty) Example: identified 191 psychiatric prescribers: 4+ non PRN psychoactive meds in 2012 (11 prescribers serving people) Letter sent to prescribers offering consult from clinical pharmacist. Clinical pharmacist followed up by phone/in person.
20 2012 Analysis of Medicaid Pharmacy Claims Data is underway Provides information on a larger, more diverse DDS population. Evaluating the methodology (data match, using Medicaid claims data) in light of new policy/funding models related to pharmacy.
21 Several recent policy changes may influencing prescription and claims patterns in the DDS population Massachusetts Health Reform MassHealth Pharmacy Intiatives MMA - Medicare Part D Dual eligible population (~ 65% of adults served) Change in formulary (e.g. benzodiazepines) Affordable Care Act duals integration efforts Medicaid Managed Care Patient Centered Medical Homes (for adults)
22 MassHealth payment claims analysis preliminary questions How many adults will the the dataset match methodology identify? Is Medicaid claims data analysis feasible, since duals would only have record of co-pays (if they are claimed by pharmacies)?
23 Linked dataset DDS- MassHealth Timeline: ~ 10+ months from initial data request for inter-agency data sharing Of 20,346 people eligible for Medicaid (from DDS), 15,069 (74%) had 1 or more paid drug claim during the 7 month period. Adults without claims include: not on any medications private insurance coverage dually eligible and had a prescription filled at a pharmacy that did not submit for the small Medicaid co-pay. Nursing home, ICF/MR, incarcerated.
24 Analysis plan and next steps Finalize data validation Analysis of individual and provider-level prescriptions patterns. Targeted outreach to providers whose prescription patterns vary substantially from accepted practice (guidelines). Identify individuals who may be in need of medication review. Evaluate prescribing practices across service settings for the purpose of planning broader training or outreach interventions.
25 Conclusion Massachusetts DDS is pursuing a multi-level approach to ensuring medications are used appropriately to support behavioral needs. Multidisciplinary team provides expertise for both individual review and for systems level interventions. Analysis of of claims data and health records allows targeted outreach.
26 Contacts: DDS Medication Review Committee janice.o 2012 CDDER Pharmacy Analysis
Massachusetts Department of Developmental Services. Medication Review
Massachusetts Department of Developmental Services Medication Review NASDDDS Reinventing Quality August 7, 2012 Alixe Bonardi 1, Gail Grossman 2 Emily Lauer 1 1 University of Massachusetts Medical School
MEDICATION USE IN ADULTS WITH ID/DD LIVING IN COMMUNITY HOMES AND STATE EFFORTS TO REDUCE OVERUSE
MEDICATION USE IN ADULTS WITH ID/DD LIVING IN COMMUNITY HOMES AND STATE EFFORTS TO REDUCE OVERUSE VALERIE BRADLEY AND DOROTHY HIERSTEINER, HSRI GAIL GROSSMAN, MASSACHUSETTS DEPARTMENT OF DEVELOPMENTAL
Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot
University of Massachusetts Medical School escholarship@umms Commonwealth Medicine Publications Commonwealth Medicine 9-28-2011 Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot Katharine
Identifying and Reducing the Risk of Falls
Identifying and Reducing the Risk of Falls A joint Project of the Massachusetts Department of Developmental Services (DDS) and UMMS/ Shriver Center s Center for Developmental Disabilities Evaluation and
Too Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities
Too Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities One definition of polypharmacy is using more medications than is medically necessary. However, it can be
Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form
Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form Please fax form to 617.673.0988 or mail to Tufts Health Plan, 705 Mount Auburn Street, Watertown, MA 02472, Attn:
$"% & '( ) " * +, !"##!""$ !*$-!+*" % $&
! """# # $"% & '( ')&# '( ) " * +, '( )(*!*$-!+*"!"##!""$ % $& &. / 011 12 ' 32 3 456 3. 3 0 11 32! 71 829:1 1' 3,3 12/ 2 31:181' 337)1 / 111 3 : 39.21)2 231 1 1 13' 223 333 23) 3;3 2 1 1' 11 3 31 333
The Pediatric Behavioral Health Medication Initiative September 2016
The Pediatric Behavioral Health Medication Initiative Neha Kashalikar, PharmD Clinical Consultant Pharmacist UMass Medical School Clinical Pharmacy Services Background Several studies investigated trends
Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care
Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care Appendices Appendix A Psych Meds Data Indicators by State The data elements being collected by the
Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017
Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
Antidepressant Prior Authorization Request
Antidepressant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
SCCMHD: Quality Improvement Medication Monitoring Chart Review Summary Report Fiscal Year: , January to March
BACKGROUND Chart review is an integral part of Mental Health Department Quality Improvement Program and mandated for clients who are Medi-Cal beneficiaries. Quality Improvement Medication Monitoring Program
Psychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
NorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017
Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
Child and Adolescent Psychiatry Trends. ADAMHS Board - 28 Oct 2014
Child and Adolescent Psychiatry Trends ADAMHS Board - 28 Oct 2014 Current Need for Child and Adolescent Psychiatrists There are currently approximately 7400 Child and Adolescent Psychiatrists in Practice
Substance Abuse Services. AIDS Drug Assistance. Oral Health Care. Program (ADAP) Medical Care
2017-2018 Council for HIV/AIDS Care and Prevention Core Medical Service Area Paired Comparison Analysis Prioritization Worksheet Medical Case Management Services Substance Abuse Services - Outpatient AIDS
Policy Evaluation: Low Dose Quetiapine Safety Edit
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503
Issues for Part D Compliance
HCCA- MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE Issues for Part D Compliance Craig Miner, RPh, JD Division of Drug Plan Policy Babette S. Edgar, Pharm.D., MBA Division of Finance and Operations
Antipsychotic Prior Authorization Request
Antipsychotic Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
Monitoring Psychotropic Use Among Foster Children EMPAA
State Plans for Monitoring Psychotropic Use Among Foster Children EMPAA October 30, 2012 Child and Family Services Improvement and Innovation Act of 2011 Required Components of Psychotropic Oversight and
Study Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
Evaluation of a Medicaid Psychotropic Drug Management Program in Utah
Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Dominick Esposito James M. Verdier 2008 SAMHSA/CMS Invitational Conference on Medicaid and Mental Health Service/Substance Abuse Treatment
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
Terri Farrell Project Director, Autism Insurance Resource Center, INDEX UMass Medical School/EK Shriver Center
Terri Farrell Project Director, Autism Insurance Resource Center, INDEX UMass Medical School/EK Shriver Center Copyright 2018 Autism Insurance Resource Center All Rights Reserved Overview Types of Insurance
Drug Use Evaluation: Low Dose Quetiapine
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Steps for Initiating Electroconvulsive Therapy Treatment
Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral
Cost of Mental Health Care
Section 4 Cost of Mental Health Care Per capita mental health spending for Americans with a mental health diagnosis has increased among children, peaking in. For adults, the spending has been more stable.
Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson
Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric
Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD
Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD Dr. Martin Katzman, BSc, MD, FRCPC Clinic Director: Staff Psychiatrist: Centre for Addiction and Mental Health
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
Table of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
Idaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: Jan. 16, 2014 Time: 9am-1pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
Integrating INTERACT into Interim Pharmacist Reviews
Integrating INTERACT into Interim Pharmacist Reviews Chad R. Worz, Pharm.D. President, Medication Managers, LLC Adjunct Assistant Professor of Pharmacy Practice, University of Cincinnati, College of Pharmacy
Medicare Part D Opioid Policies for 2019 Information for Patients
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Opioid Policies for 2019 Information for Patients Introduction Prescription opioid pain medications like oxycodone (OxyContin ), hydrocodone (Vicodin
Medicaid Perspective
Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:
New Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services
New Jersey Department of Children and Families Policy Manual Manual: CP&P Child Protection and Permanency Effective Volume: V Health Date: Chapter: A Health Services 1-11-2017 Subchapter: 1 Health Services
Abilify (aripiprazole)
Abilify (aripiprazole) FDA ALERT [04/2005] Abilify is a type of medicine called an atypical antipsychotic. FDA has found that older patients treated with atypical antipsychotics for dementia had a higher
IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
Medications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
Limiting the Duration of Medication Assisted Treatment for Opioid Addiction: Will New State Policies Help or Hurt?
University of Massachusetts Medical School escholarship@umms Commonwealth Medicine Publications Commonwealth Medicine 6-25-2014 Limiting the Duration of Medication Assisted Treatment for Opioid Addiction:
Anticonvulsant Prior Authorization Request
Anticonvulsant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
National Professional Development Center on Autism Spectrum Disorders
National Professional Development Center on Autism Spectrum Disorders Parent and Child Information Questionnaire Thank you for taking time to complete this questionnaire. This information will help us
Antipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
Medi Cal Managed Care. Melissa Lamer, PharmD, BCPP July 31 st, 2014
Pharmacy Benefit Carve Outs in Medi Cal Managed Care Melissa Lamer, PharmD, BCPP July 31 st, 2014 2 The Behavioral Health Carve Out Services Carved Out to the County Starting 1/1/2014 Medi Cal plans now
Antidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
Idaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:
MEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015
Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead
MassHealth Tobacco Cessation Program Benefit
MassHealth Tobacco Cessation Program Benefit Fact Sheet for Providers Overview of the New Benefit Effective July 1st, 2006, MassHealth members (Medicaid recipients in Massachusetts) have access to tobacco
Cerebral Stimulant and ADHD Drugs Prior Authorization Request
Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization
Long Term Services Division. Supersedes: Policy Governing Behavior Support Service Planning, 1/19/96 and LTSD Behavior Support Policy Revision 6/23/00
Department of Health Long Term Services Division POLICY Policy Title: Psychotropic Medication Use Policy Number: Supersedes: Policy Governing Behavior Support Service Planning, 1/19/96 and LTSD Behavior
2. Did the member receive this medication during a recent hospitalization? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Antipsychotics (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
2. Did the patient receive this medication during a recent hospitalization? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Antipsychotics (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA
*We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening
Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica
Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
Improving Dementia Care in Nursing Homes Through Best Care Practices
Improving Dementia Care in Nursing Homes Through Best Care Practices Morris J. Kaplan, Esq., NHA President, Kaplan Health Management, LLC Operating Partner, Gwynedd Square Nursing Center 5 Star Rated by
Value of Hospice Benefit to Medicaid Programs
One Pennsylvania Plaza, 38 th Floor New York, NY 10119 Tel 212-279-7166 Fax 212-629-5657 www.milliman.com Value of Hospice Benefit May 2, 2003 Milliman USA, Inc. New York, NY Kate Fitch, RN, MEd, MA Bruce
AAA. add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
AAA Adolescents & Adults with Autism A Study of Family Caregiving add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
Beyond Diagnosis: My Patient Has Autism, Now What? Vanessa Kimm, MSN, RN, ARNP, CPNP. Objectives 4/18/2017
Beyond Diagnosis: My Patient Has Autism, Now What? Vanessa Kimm, MSN, RN, ARNP, CPNP Objectives Discuss the complex challenges families face after their child receives an autism diagnosis Identify current
Autism Spectrum Disorder Services
Autism Spectrum Disorder Services Autism Spectrum Disorder Services, CT 2 Background The CT Behavioral Health Partnership was formed in 2005 between the Department of Social Services (DSS), the Department
A lmost all patients admitted to hospital receive prescribed
4 ORIGINAL ARTICLE The use of prescribing indicators to measure the quality of care in psychiatric inpatients C Paton, P Lelliott... See editorial commentary, p 9 See end of article for authors affiliations...
Antipsychotic use in Dementia care. Jabbar Fazeli, MD
Antipsychotic use in Dementia care Jabbar Fazeli, MD www.mainegeriatrics.com What changed in 2012? NY times- May 9, 2011!! Antipsychotic Drugs Called Hazardous for the Elderly - referencing the OIG audit
Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline
American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline I. Geriatric Psychiatry Patient Care and Procedural Skills Core Competencies A. Geriatric psychiatrists shall
Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services
Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care Illinois Department of Children and Family Services Introduction With few exceptions, children and adolescents in
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) PDMP West Regional Meeting PMP Collaboration with the NM Department of Health April 26, 2018 New Mexico Board of Pharmacy Prescription
4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
The NYC Elder Abuse Center
The NYC Elder Abuse Center Brooklyn Geriatric Mental Health and Medical Provider Survey You can also complete this survey online: http://www.surveymonkey.com/s/geriatricproviders PLEASE PRINT CLEARLY Preamble
Public Policy Agenda 2016
Public Policy Agenda 2016 1 in 26 Americans will have epilepsy over the course of their lifetime. Nearly three million children and adults in the United States have epilepsy. Epilepsy is defined as an
Prescription drug expenditures are the most rapidly growing component
Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid Kenneth S. Fink, MD, MGA, MPH 1 Patricia J. Byrns, MD 2 1 Department of Family Medicine, University of North Carolina
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
National Litigation Trends
National Litigation Trends Caroline M. Brown, Esq. Covington & Burling LLP NASMHPD/NASDDDS Legal Divisions Meeting November 13, 2012 Certification of Psychiatric Hospitals Pending OIG audits in several
OBJECTIVES. 1. Become familiar with common classes of psychotropic medications, indications for their use, and side effects.
OBJECTIVES 1. Become familiar with common classes of psychotropic medications, indications for their use, and side effects. 2. Use familiar conditions, as drawn from current caseloads, to evaluate the
Recommended Geropsychiatric Competency Enhancements for Gerontological Nurse Practitioners
Recommended Geropsychiatric Competency Enhancements for Gerontological Nurse Practitioners These recommended competency enhancement statements draw attention to the special needs of older adults with mental
WA PMP Access by Public Payers. PDMP North Regional Meeting St. Louis, MO April 23-24
WA PMP Access by Public Payers PDMP North Regional Meeting St. Louis, MO April 23-24 Public Insurer Access PDMP Statute: Allows PDMP data to be provided to Medicaid and Workers Compensation Primary Goal:
News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics
Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage
Making Sense of the Long Term Care Mega Rule: Unnecessary Drugs & Psychotropics. Session Objectives. January 2018
Making Sense of the Long Term Care Mega Rule: Unnecessary Drugs & Psychotropics Bridget McCrate Protus, PharmD, MLIS, BCGP, CDP Director of Drug Information Optum Hospice Pharmacy Services Session Objectives
Palliative Care Quality Improvement Program (QIP) Measurement Specifications
Palliative Care Quality Improvement Program (QIP) 2017-18 Measurement Specifications Developed by: QIP Team Contact: palliativeqip@partnershiphp.org Published on: October 6, 2017 Table of Contents Program
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
Ohio Psychotropic Medication Quality Improvement Collaborative. Minds Matter. Toolkit. for You and Your Family. This is the property of
Minds Matter Ohio Psychotropic Medication Quality Improvement Collaborative Minds Matter Toolkit for You and Your Family This is the property of About Minds Matter Minds Matter is a project to help teens,
STATE ALZHEIMER S DISEASE PLANS: TRAINING
STATE ALZHEIMER S DISEASE PLANS: TRAINING Recommendations to better equip health care professionals and others to deal with individuals with Alzheimer s Arkansas California Colorado Illinois Iowa Integrate
Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives
Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Mary Elizabeth Jones, Pharm BSc, RPh Senior Pharmacist AHCA Pharmacy
Bock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201
Bock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201 State Project Director- Bliss Beeman, RN Clinical Associate- Shelley Smith, RN Administrative Assistant- Viki DeClerk bockarkansas@gmail.com
PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE
PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE Introduction and General Principles April 2017 Adapted for New Mexico from with permission from the Texas Department
Changing patterns of sedative use over time in older adults in Ontario
Changing patterns of sedative use over time in older adults in Ontario Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehabilitation Institute University Health Network Faculty/Presenter Disclosure Faculty: Andrea
Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
June 2008 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair); Dennis Chapron, M.S.; Richard Gannon, Pharm.D.; Keith Lyke R.Ph., Mike Moore, R.Ph., MPH; Bhupesh Mangla, M.D., Ram Illindala,
Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
2012 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members
2012 Chronic Respiratory Program Evaluation Our mission is to improve the health and quality of life of our members 2012 Chronic Respiratory Program Evaluation Program Title: Chronic Respiratory Program
Iowa Medicaid Mental Health Advisory Group Meeting February 13, Tentative Agenda
CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Mental Health Advisory Group Meeting February 13, 2009 Location: Iowa Medicaid
Drug Utilization Review Board
DUR Members present DUR members absent MDCH/MMA/MPA present Steven Bernstein, M.D., Chair Carrie Germain, R. Ph, Vice Chair Bob DeYoung, PharmD James Forshee, M.D. Debera Eggleston, M.D. Sahar Swiden,
Behavioral Health Treatment in a Primary Care Setting
Behavioral Health Treatment in a Primary Care Setting Andrew J. McLean, MD, MPH Medical Director, ND DHS Chair, Psychiatry and Behavioral Science, UNDSMHS ajmclean@nd.gov Objectives Understand the importance
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER 1.1 GENERAL PRINCIPLES There are many causes of agitation in palliative care patients, which makes recommendations for treatment difficult.